Overview A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients Status: Unknown status Trial end date: 2020-12-01 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer. Phase: Phase 1/Phase 2 Details Lead Sponsor: Qilu Pharmaceutical Co., Ltd.